WallStreetZen

NASDAQ: PSNL
Personalis Inc Stock Forecast, Predictions & Price Target

Analyst price target for PSNL

Based on 6 analysts offering 12 month price targets for Personalis Inc.
Min Forecast
$28.00+42.57%
Avg Forecast
$37.67+91.79%
Max Forecast
$50.00+154.58%

Should I buy or sell PSNL stock?

Based on 6 analysts offering ratings for Personalis Inc.
Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

PSNL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Needham
Top 7%
94
BuyMaintains$28.00+42.57%2021-09-20
Anonymous
Morgan Stanley
Strong BuyMaintains$35.00+78.21%2021-05-07
Oppenheimer
Top 3%
98
BuyUpgrades$28.00+42.57%2021-05-06
Truist Securities
Top 3%
98
Strong BuyInitiates Coverage On$50.00+154.58%2021-01-28
HC Wainwright & Co.
Top 3%
98
BuyMaintains$50.00+154.58%2021-01-13
Citigroup
Top 3%
98
Strong BuyInitiates Coverage On$35.00+78.21%2020-10-19

1 of 1

Forecast return on equity

Is PSNL forecast to generate an efficient return?
Company
2.88%
Industry
47.75%
Market
2,530.71%
PSNL's Return on Equity is forecast to be low in 3 years (2.88%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is PSNL forecast to generate an efficient return on assets?
Company
2.55%
Industry
15.95%
Market
1,237.48%
PSNL is forecast to generate lower Return on Assets (2.55%) than the US Diagnostics & Research industry average (15.95%)
Forecast

PSNL earnings per share forecast

What is PSNL's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.53+22.4%
Avg 2 year Forecast
-$1.89+51.2%
Avg 3 year Forecast
-$1.11-11.2%

PSNL revenue forecast

What is PSNL's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$85.0M+3.03%
Avg 2 year Forecast
$95.2M+15.29%
Avg 3 year Forecast
$131.3M+59.09%
PSNL's revenue is forecast to grow at a rate of 14.49% per year, which is not exceptional
Forecast

PSNL revenue growth forecast

How is PSNL forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
14.49%
Industry
11.42%
Market
12.37%
PSNL's revenues are forecast to grow faster (14.49% per year) than the US Diagnostics & Research industry average (11.42%)
Forecast
PSNL's revenues are forecast to grow faster (14.49% per year) than the US market average (12.37%)
Forecast

Personalis Stock Forecast FAQ

Is Personalis Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: PSNL) stock is to Strong Buy PSNL stock.

Out of 6 analysts, 3 (50%) are recommending PSNL as a Strong Buy, 3 (50%) are recommending PSNL as a Buy, 0 (0%) are recommending PSNL as a Hold, 0 (0%) are recommending PSNL as a Sell, and 0 (0%) are recommending PSNL as a Strong Sell.

What is PSNL's earnings growth forecast for 2021-2023?

(NASDAQ: PSNL) Personalis's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 16.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.62%.

Personalis's earnings in 2021 is -$50,243,000.On average, 4 Wall Street analysts forecast PSNL's earnings for 2021 to be $-67,951,099, with the lowest PSNL earnings forecast at $-68,839,349, and the highest PSNL earnings forecast at $-67,062,849. On average, 4 Wall Street analysts forecast PSNL's earnings for 2022 to be $-83,939,593, with the lowest PSNL earnings forecast at $-95,930,963, and the highest PSNL earnings forecast at $-71,504,098.

In 2023, PSNL is forecast to generate $-49,297,856 in earnings, with the lowest earnings forecast at $-75,501,221 and the highest earnings forecast at $-23,094,491.

What is PSNL's revenue growth forecast for 2021-2023?

(NASDAQ: PSNL) Personalis's forecast annual revenue growth rate of 14.49% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 11.42%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 12.37%.

Personalis's revenue in 2021 is $82,543,000.On average, 4 Wall Street analysts forecast PSNL's revenue for 2021 to be $3,776,926,379, with the lowest PSNL revenue forecast at $3,773,728,681, and the highest PSNL revenue forecast at $3,783,943,552. On average, 4 Wall Street analysts forecast PSNL's revenue for 2022 to be $4,226,602,770, with the lowest PSNL revenue forecast at $3,153,286,293, and the highest PSNL revenue forecast at $4,756,576,929.

In 2023, PSNL is forecast to generate $5,832,202,855 in revenue, with the lowest revenue forecast at $5,814,837,574 and the highest revenue forecast at $5,849,568,136.

What is PSNL's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: PSNL) forecast ROA is 2.55%, which is lower than the forecast US Diagnostics & Research industry average of 15.95%.

What is PSNL's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PSNL price target, the average PSNL price target is $37.67, with the highest PSNL stock price forecast at $50.00 and the lowest PSNL stock price forecast at $28.00.

On average, Wall Street analysts predict that Personalis's share price could stay at $37.67 by Sep 20, 2022. The average Personalis stock price prediction forecasts a potential downside of N/A from the current PSNL share price of $19.64.

What is PSNL's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: PSNL) Personalis's current Earnings Per Share (EPS) is -$1.25. On average, analysts forecast that PSNL's EPS will be $-1.53 for 2021, with the lowest EPS forecast at $-1.55, and the highest EPS forecast at $-1.51. On average, analysts forecast that PSNL's EPS will be $-1.89 for 2022, with the lowest EPS forecast at $-2.16, and the highest EPS forecast at $-1.61. In 2023, PSNL's EPS is forecast to hit $-1.11 (min: $-1.70, max: $-0.52).

What is PSNL's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: PSNL) forecast ROE is 2.88%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.